Loading...
Silverback Therapeutics, Inc.
SBTX•NASDAQ
HealthcareBiotechnology
$5.87
$0.06(1.03%)
Silverback Therapeutics, Inc. (SBTX) Stock Overview
Explore Silverback Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for SBTXStats details for SBTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for SBTXAnalyst Recommendations details for SBTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
CEO
Dr. Peter A. Thompson M.D.
Employees
90
Headquarters
500 Fairview Avenue North, Seattle, WA
Founded
2020